Inflammation  >>  opicinumab (BIIB033)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
opicinumab (BIIB033) / Biogen
AFFINITY, NCT03222973 / 2017-001224-22: Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

Terminated
2
263
Europe, Canada, US, RoW
BIIB033 (opicinumab), Placebo
Biogen
Multiple Sclerosis
02/21
02/21

Download Options